3 Pharmacotherapeutic potential of GIP and GLP-1 3.1 Therapeutic potential in T2DM Despite being the first identified incretin, GIP was initially disregarded as a viable therapeutic approach for T2DM
More substantial changes can be expected after approximately four weeks
Symptoms appeared within weeks of reaching the highest dose, and in patients who discontinued the medication, symptoms resolved
Rapid weight loss, which semaglutide can cause, is a known risk factor for gallstones
Patients should not discontinue semaglutide without consulting their healthcare provider, particularly those using it for type 2 diabetes management
P = 0.004), in comparison with 2 mg, for the treatment policy estimand and the hypothetical estimand, respectively, and of 2.5 kg (not statistically significant) and 4.2 kg in comparison with 8 mg (Fig